Table 2.

Molecular features of AML patients relapsed after tyrosine kinase inhibitors (TKIs) treatment.

	BM blasts (%)	NPM1	FLT3-ITDmut	FLT3-ITDmut AR	Size FLT3-ITDmut clone	Relapse (months)	TKI treatment
UPN13
Diagnosis	20	Wild-type	mut	0.05	31 bp	5	Midostaurin
Relapse	70	Wild-type	Wild-type	/	/
UPN14
Diagnosis	83	mut	mut	0.75	17 bp; 81 bp	13	Midostaurin
Relapse	74	mut	mut	3.97	81 bp
UPN15
Diagnosis	70	mut	mut	0.44	40 bp; 60 bp	14	Midostaurin
Relapse	30	mut	mut	0.2	40 bp
UPN16
Diagnosis	62	mut	mut	0.4	57 bp	8	Quizartinib
Relapse	85	mut	mut	0.42	57 bp